Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

e-ULTIMASTER Trial

22/05/2019 -  

​One of the largest, prospective worldwide registries


Designed to

  • Further validate the safety and efficacy of Ultimaster™ family DES system in unselected patients representing everyday clinical practice

  • Further explore the performance of Ultimaster™ family DES in large complex patient and lesions subsets


Ultimaster™ family consists of Ultimaster™ and Ultimaster™ Tansei™ Sirolimus Eluting Stents. 


Study Design

Prospective, single arm, multi-centre, observational registry

37,000+ patients

376 sites worldwide

50 countries


Primary Outcome Measure:

Target lesion failure (TLF) defined as a composite of cardiac death, target vessel related myocardial infarction (MI)

and clinically driven target lesion revascularization (TLR) at 1 year






Total Population

In 25,000+ patients, e-Ultimaster shows 1-year target lesion failure rate of 3.3.%


Primary endpoint: target lesion failure at 1 year

Cardiac death, target-vessel myocardial infarction or clinically-driven target lesion revascularization

n=25'990

Roffi M., presented at euroPCR2019



Bifurcation Lesions

Reporting a low target lesion failure rate of 5.2 % at 1year in bifurcation lesions


1-year clinical outcomes
Bifurcation, n=3'372 patients

CD-TLR: clinically driven target lesion revascularization; CD-TVR: clinically driven target vessel revascularization; MI: myocardial infarction; ST: definite+probable stent thrombosis; TLF: target lesion failure (a composite of cardiac death, target-vessel MI or CD-TLR)

Chevalier B., presented at euroPCR2019


Left Main

Providing a safe and good option for the treatment of left main lesions 


1-year clinical outcomes

Left main, n=840 patients




LM: left main; MI: myocardial infarction; ST: definite + probable stent thrombosis; TLF: target lesion failure (a composite of cardiac death, target-vessel MI or clinically-driven TLR); TLR: target lesion revascularization; TVF: target vessel failure (composite of cardiac death, target-vessel MI or clinically-driven target-vessel revascularization);

Angioi M.; presented at euroPCR2019


CTO

Real-world good clinical outcomes in complex CTO patients


1-year clinical outcomes
Chronic total occlusion, n=1309

CD-TLR: clinically-driven target lesion revascularization; MI: myocardial infarction; ST: definite + probable stent thrombosis; TLF: target lesion failure (composite of cardiac death, target vessel MI and CD-TLR); TVF: target vessel failure (composite of cardiac death, target vessel MI and clinically-driven target vessel revascularization


Rumoroso J.; presented at euroPCR2019


Multivessel Disease

Complete revascularization results in good clinical outcomes in all MVD patients and STEMI MVD patients


1-year clinical outcomes
All multivessel disease patients


Results based on propensity score weighted analysis 

Results based on propensity score weighted analysis 





CD-TLR: clinically-driven target lesion revascularization; MI: myocardial infarction; POCE: patient-oriented composite endpoint ( a composite of all-cause mortality, any MI, any revascularization); ST: definite + probable stent thrombosis; STEMI: ST-elevated myocardial infarction; TLF: target lesion failure (a composite of cardiac death, TV-MI and clinically driven target lesion revascularization)

Hildick-Smith D., presented at euroPCR2019